The Global Amyotrophic Lateral Sclerosis Treatment Market was valued at USD 634 Million in 2023 and expected to grow USD 1021 Million in 2032.

Coya Therapeutics is entering into a phase 2b study for its ALS, and the biotech’s CEO believes it’s on the cusp of a game changer.

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Cai, now 46, was diagnosed with amyotrophic lateral sclerosis (ALS), a progressive neurodegenerative disease that affects nerve cells in the brain and spinal cord, back in 2019. As one of the most ...

The ALS Association will host its second ALS Nexus conference in August, with the goal of making the disease a livable one ...

Amylyx Pharmaceuticals, Inc. ("Amylyx" or the "Company") today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold placed on the Phase 1 clinical trial of AMX0114, ...

targeting calpain-2 for people living with amyotrophic lateral sclerosis (ALS). With the clinical hold lifted, Amylyx is now working to open U.S. sites for screening, enrollment, and dosing.

Nussbaum, 71, was diagnosed two years ago with amyotrophic lateral sclerosis, a progressive disease also known as Lou Gehrig's disease that attacks nerve cells that control muscles throughout the ...

Background/aims: Oro-pharyngeal dysfunction has been reported in Amyotrophic Lateral Sclerosis (ALS). We aimed to assess ALS patients upper gastrointestinal (GI) motor activity and GI symptoms ...

An expansion of a hexanucleotide repeat in the C9ORF72 gene can cause ALS. Here, the authors develop a high-fidelity RNA-targeting CRISPR system to suppress the repeat RNA expressed from the ...